ICUI — ICU Medical, Inc.

ICU Medical, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: $536 million, representing a 2% organic growth but a reported decline of 14% due to the deconsolidation of IV Solutions.
• Full Year 2025 Revenue Growth: 5% organic growth.
• Gross Margin: Maintained above 40%, specifically at 40.5% for Q4.
• EBITDA: $98 million, down 7% from $106 million year-over-year, impacted by deconsolidation and tariffs.
• EPS: $1.91, a decline of 9% from $2.11 in the previous year.
• Free Cash Flow: $44 million for Q4; total for 2025 was $100 million.
• Net Debt: Approximately $1 billion, with a leverage ratio just below 2.5x.

2. Strategic Updates and Business Highlights:

• Business Performance: Both consumables and systems businesses achieved record revenue quarters. Consumables grew 6% reported and 5% organic in Q4.
• Operational Improvements: Successful closure of an FDA warning letter for Smiths Medical, allowing for more strategic choices.
• Product Development: Progress on 510(k) submissions for new syringe pumps and safety software, aiming for FDA clearances in mid-2026.
• Manufacturing Integration: Completed integration of two legacy manufacturing sites, expected to yield benefits as inventory depletes.

3. Forward Guidance and Outlook:

• 2026 Revenue Growth: Expected to be in the low to mid-single-digit range, with similar growth rates for consumables and infusion systems.
• Gross Margin Guidance: Projected to be around 41% for the full year, with improvements anticipated as integration and consolidation efforts finalize.
• EBITDA Guidance: Expected in the range of $400 million to $430 million for 2026.
• Free Cash Flow Improvement: Anticipated to be better than 2025, driven by higher earnings and reduced spending on restructuring.

4. Bad News, Challenges, or Points of Concern:

• Deconsolidation Impact: The divestiture of IV Solutions significantly affected revenue and EBITDA, with an estimated $25 million impact on Q4 adjusted EBITDA.
• Tariff Expenses: Continued tariff costs are expected to impact margins, projected at approximately 2% of revenue.
• Vital Care Business: Experienced a 6% organic decline and a 35% reported decline due to deconsolidation; future revenue is expected to be flat to slightly down as the company focuses on profitability.
• Regulatory Risks: While the FDA warning letter has been resolved, ongoing regulatory scrutiny remains a concern.

5. Notable Q&A Insights:

• Market Environment: The capital environment remains stable, with customers actively making decisions. However, there are signs of deceleration in baseline hospital utilization.
• Product Transition: There is confidence in the transition to new products (Plum Duo and Solo) and an expectation that this will drive growth, particularly in the second half of 2026.
• OEM Wind Down: The exit of a declining OEM customer is anticipated to impact sales, but the company has managed to grow despite this headwind.
• Future Opportunities: The company is optimistic about capturing market share in the syringe pump segment and leveraging the integration of its product offerings for better customer retention and satisfaction.

Overall, ICU Medical is navigating through a transitional phase with strategic initiatives aimed at improving operational efficiency and product offerings while managing the impacts of external challenges such as tariffs and market dynamics.